Dr. Manuj Sondhi, Consultant Physician and Diabetologist at Nirvana Clinic, Greater Noida, was quoted by Channel NewsAsia (CNA) in its report on India's fast-growing weight-loss drug market and the rising availability of semaglutide and other GLP-1 medicines for obesity and diabetes care.
Speaking to CNA about the surge in demand following India's generic semaglutide launch, Dr. Sondhi noted that interest had spiked not only among patients with a medical need, but also among those seeking weight loss for cosmetic reasons — and that the real value of these medicines lies in preventing more serious metabolic disease.
"Obesity itself is a risk factor for a lot of metabolic issues — it can increase cardiac risk, hypertension and diabetes."— Dr. Manuj Sondhi, quoted in CNA, 30 April 2026
You can read the full report on Channel NewsAsia.
The collapse in the price of semaglutide has made effective metabolic treatment accessible to far more people — which is genuinely good news. But cheaper access also means more people starting these medicines without assessment, and that is where harm creeps in. GLP-1 medicines can be valuable, but they are prescription treatments, not lifestyle purchases, and they are not right for everyone.
Before starting any patient on a GLP-1 medicine at Nirvana Clinic, the assessment includes:
This is the difference between a medicine that helps and one that causes avoidable harm. If you are considering treatment, the right first step is a proper medical weight-loss evaluation — not a walk into a pharmacy.
Physician-supervised, evidence-based metabolic care — the right patient, the right medicine, the right follow-up.
Consultant Physician & Diabetologist at Nirvana Clinic, Greater Noida, and Visiting Consultant at Fortis Hospital. 15+ years in metabolic medicine; 17 peer-reviewed publications. Read full profile →